S. Yoon

发表

Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly Subjects

K. Yu, K. Jang, J. Chung, 2016, Journal of clinical pharmacology.

Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects

Joo-Youn Cho, K. Yu, Jae-Yong Chung, 2019, Scientific Reports.

Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females

A. Kim, Joo-Youn Cho, K. Yu, 2017, The AAPS Journal.

Pharmacokinetics and effect on the corrected QT interval of single-dose escitalopram in healthy elderly compared with younger adults

Sang-In Park, Joo-Youn Cho, K. Yu, 2017, International clinical psychopharmacology.

The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.

J. Kim, Joo-Youn Cho, K. Yu, 2009, Clinical therapeutics.

The Effect of the Newly Developed Angiotensin Receptor II Antagonist Fimasartan on the Pharmacokinetics of Atorvastatin in Relation to OATP1B1 in Healthy Male Volunteers

Min Goo Lee, Joo-Youn Cho, K. Yu, 2011, Journal of cardiovascular pharmacology.

Effectiveness of increasing the frequency of posaconazole syrup administration to achieve optimal plasma concentrations in patients with haematological malignancy.

Sang-In Park, Y. Koh, P. G. Choe, 2016, International journal of antimicrobial agents.

Incidence and Risk Factors of Immediate Hypersensitivity Reactions Associated With Low-Osmolar Iodinated Contrast Media: A Longitudinal Study Based on a Real-Time Monitoring System

J. Kim, Sang-Heon Cho, Hye‐Ryun Kang, 2019, Journal of Investigational Allergology and Clinical Immunology.

The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.

P. G. Choe, N. Kim, M. Oh, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.

Joo-Youn Cho, K. Yu, I. Jang, 2012, Clinical therapeutics.

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects

Joo-Youn Cho, K. Yu, I. Jang, 2021, Drug design, development and therapy.

DDDT_A_303772 1735..1747

Joo-Youn Cho, K. Yu, I. Jang, 2021 .

Prolonged Use of Aspirin Alters Human and Rat Intestinal Cells and Thereby Limits the Absorption of Clopidogrel

J. Roh, K. Chu, Soon-Tae Lee, 2011, Clinical pharmacology and therapeutics.

Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice.

S. Chung, J. Sung, S. Yoon, 2007, Biological & pharmaceutical bulletin.

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers

Sumin Yoon, Joo-Youn Cho, K. Yu, 2017, Drug design, development and therapy.

Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects

Joo-Youn Cho, K. Yu, I. Jang, 2017, Drug design, development and therapy.

A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea

Jinny Park, J. Cheong, C. Jung, 2018, Cancer medicine.

Effects of Proton Pump Inhibitors on Metformin Pharmacokinetics and Pharmacodynamics

Joo-Youn Cho, K. Yu, I. Jang, 2014, Drug Metabolism and Disposition.

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects

Joo-Youn Cho, K. Yu, S. Schneider, 2014, Drug design, development and therapy.

Pharmacokinetics and Tolerability Evaluation of Human Coagulation Recombinant Factor VIII (GreenGene^TM) in Hemophilia A Patients

Joo-Youn Cho, K. Yu, Jae-Yong Chung, 2011 .

Pharmacokinetic–Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy Volunteers

Joo-Youn Cho, K. Yu, Jung-Ryul Kim, 2013, Basic & clinical pharmacology & toxicology.

Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state

Joo-Youn Cho, K. Yu, I. Jang, 2014, Drug design, development and therapy.

Simultaneous LC–MS–MS Determination of HM30181A, [2-(2-{4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]amide, as a new P-Glycoprotein Inhibitor and Its Two Metabolites, M1 and M2, in Human Plasma: Application to a Pharmacokinetic Study

Y. Choi, Joo-Youn Cho, K. Yu, 2011 .

Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function

S. Ji, Joo-Youn Cho, Jae-Yong Chung, 2020, Clinical pharmacology in drug development.

Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects

Joo-Youn Cho, K. Yu, I. Jang, 2016, Drug design, development and therapy.

Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover

Joo-Youn Cho, K. Yu, I. Jang, 2011, Clinical therapeutics.

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles

Joo-Youn Cho, K. Yu, I. Jang, 2015, Drug design, development and therapy.

Global metabolomics and targeted steroid profiling reveal that rifampin, a strong human PXR activator, alters endogenous urinary steroid markers.

Joo-Youn Cho, K. Yu, I. Jang, 2013, Journal of proteome research.

Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc‐fused interleukin‐1 receptor antagonist, in healthy subjects: A first‐in‐human study

Hyunyee Yoon, S. Yoon, Howard Lee, 2020, British journal of clinical pharmacology.

Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers

Joo-Youn Cho, K. Yu, I. Jang, 2012, Journal of clinical pharmacology.

Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis

K. Yu, S. Yoon, S. Shin, 2019, Antimicrobial Agents and Chemotherapy.

Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects.

Sumin Yoon, A. Kim, Yujin Lee, 2020, Drug metabolism and pharmacokinetics.

The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects.

Sumin Yoon, A. Kim, Yujin Lee, 2020, Drug metabolism and pharmacokinetics.

Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.

A. Kim, Joo-Youn Cho, K. Yu, 2019, Drug metabolism and pharmacokinetics.

Comparative pharmacokinetics of Theracurmin, a highly bioavailable curcumin, in healthy adult subjects

Ji-Young Park, Joo-Youn Cho, S. Yoon, 2021, International journal of clinical pharmacology and therapeutics.

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects

Joo-Youn Cho, K. Yu, S. Yoon, 2016, Drug Design, Development and Therapy.

Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers.

K. Yu, I. Jang, S. Yoon, 2009, Clinical therapeutics.

Genetic Polymorphisms of the Carboxylesterase 1 (CES1) Gene in a Korean Population

Eun-Young Kim, Joo-Youn Cho, K. Yu, 2014 .

Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase‐4 inhibitor, evogliptin (DA‐1229)

A. Kim, Joo-Youn Cho, K. Yu, 2017, Diabetes, obesity & metabolism.

Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel DPP-IV inhibitor , evogliptin ( DA-1229 )

Joo-Youn Cho, K. Yu, I. Jang, 2016 .

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

Sang-Heon Cho, Joo-Youn Cho, K. Yu, 2014, Drug design, development and therapy.

Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.

Joo-Youn Cho, K. Yu, I. Jang, 2012, Clinical therapeutics.

Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects

K. Yu, Jae-Yong Chung, S. Yoon, 2021, Clinical pharmacology in drug development.

Population Pharmacokinetics of Theophylline in Premature Korean Infants

Joo-Youn Cho, K. Yu, I. Jang, 2013, Therapeutic drug monitoring.

Pharmacokinetics and Tolerability Evaluation of Fudosteine after Oral Administration in Healthy Korean Volunteers

Joo-Youn Cho, K. Yu, Jae-Yong Chung, 2011 .

The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension

Sang-In Park, Y. Koh, P. G. Choe, 2018, Antimicrobial Agents and Chemotherapy.